The sales of antihypertensive medicine in Austria are forecasted to experience a steady increase from 2024 to 2028, growing from 51.3 million Euros to 52.6 million Euros. The year-on-year variation from 2024 to 2025 is approximately 0.78%, from 2025 to 2026 is roughly 0.58%, from 2026 to 2027 is about 0.58%, and from 2027 to 2028 is close to 0.57%. The compound annual growth rate (CAGR) over the five-year forecast period from 2024 to 2028 is projected at approximately 0.63%.
Future trends to watch for:
- Emerging technologies in drug delivery systems.- Introduction of new, more effective antihypertensive medications.- Government healthcare policies influencing medication usage and pricing.- Demographic changes such as an aging population, leading to higher demand.- Increased healthcare awareness and screenings for hypertension.
